Core Viewpoint - Shanghai Pharmaceuticals announced the approval of its Dihydroxypropyl Theophylline Injection by the National Medical Products Administration, indicating successful compliance with the consistency evaluation of generic drug quality and efficacy [1] Company Summary - Shanghai Pharmaceuticals' subsidiary, Shanghai Xinyi Jinzhu Pharmaceutical Co., Ltd., received the approval notification for Dihydroxypropyl Theophylline Injection [1] - The injection is indicated for the relief of symptoms in bronchial asthma, asthmatic bronchitis, obstructive pulmonary emphysema, and can also be used for wheezing due to cardiogenic pulmonary edema [1]

Core Viewpoint - Goldman Sachs reported that Shanghai Pharmaceuticals (02607) had a second-quarter sales of 70.8 billion RMB, a year-on-year increase of 2.3%, which was below expectations, indicating continued weakness across various market segments [1] Financial Performance - The second-quarter recurring net profit was consistent with well-controlled expenditures, but was partially offset by a decline in gross margin [1] - The decline in gross margin was primarily attributed to the ongoing decrease in manufacturing profit margins [1] Earnings Forecast - Goldman Sachs adjusted the company's earnings forecasts for this year, next year, and 2027 to an increase of 33.5%, a decrease of 0.3%, and a decrease of 6.4%, respectively [1] - The target price was lowered from 10.29 HKD to 10.08 HKD, maintaining a "Sell" rating [1]

Core Viewpoint - Goldman Sachs reports that Shanghai Pharmaceuticals (601607)(02607) experienced a second-quarter sales revenue of 70.8 billion RMB, a year-on-year increase of 2.3%, which is below expectations, indicating continued weakness across various market segments [1] Financial Performance - The second-quarter recurring net profit was consistent with well-controlled expenditures, but was partially offset by a decline in gross margin [1] - The decline in gross margin is primarily attributed to the ongoing decrease in manufacturing profit margins [1] Earnings Forecast - The company’s earnings forecasts for this year, next year, and 2027 have been adjusted to an increase of 33.5%, a decrease of 0.3%, and a decrease of 6.4%, respectively [1] - The target price has been lowered from 10.29 HKD to 10.08 HKD, while maintaining a "Sell" rating [1]

证券代码：601607 证券简称：上海医药 编号：临 2025-081 上海医药集团股份有限公司 关于二羟丙茶碱注射液通过仿制药一致性评价的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 近日，上海医药集团股份有限公司（以下简称"公司"）下属上海信谊金朱 药业有限公司（以下简称"信谊金朱"）的二羟丙茶碱注射液（以下简称"该药 品"）收到国家药品监督管理局（以下简称"国家药监局"）颁发的《药品补充 申请批准通知书》（通知书编号：2025B04012），该药品通过仿制药质量和疗 效一致性评价。 一、该药品基本情况 药物名称：二羟丙茶碱注射液 剂型：注射剂 规格：2ml:0.3g 注册分类：化学药品 药品批准文号：国药准字 H20258173 申请人：上海信谊金朱药业有限公司 审批结论：批准本品增加 2ml:0.3g 规格的补充申请，核发药品批准文号，本 品通过仿制药质量和疗效一致性评价。 二、该药品相关的信息 二羟丙茶碱注射液适用于支气管哮喘、喘息型支气管炎、阻塞性肺气肿等缓 解喘息症状。也可用于因心源性肺水肿而致的喘 ...

Core Viewpoint - Shanghai Pharmaceuticals (601607) announced that its subsidiary, Shanghai Xinyi Jinzhu Pharmaceutical Co., Ltd., received the approval notice from the National Medical Products Administration for its Dihydrocodeine Injection, which has passed the consistency evaluation of quality and efficacy for generic drugs [1] Group 1 - The Dihydrocodeine Injection is indicated for the relief of symptoms in bronchial asthma, asthmatic bronchitis, and obstructive pulmonary emphysema [1] - The drug can also be used for alleviating symptoms caused by pulmonary edema due to heart disease [1]

Core Viewpoint - Shanghai Pharmaceuticals (601607.SH) announced that its subsidiary, Shanghai Xinyi Jinzhu Pharmaceutical Co., Ltd. (referred to as "Xinyi Jinzhu"), has received a "Drug Supplement Application Approval Notice" from the National Medical Products Administration (NMPA) for its Dihydroxypropyl Theophylline Injection, which has passed the consistency evaluation of quality and efficacy for generic drugs [1] Group 1 - The Dihydroxypropyl Theophylline Injection is indicated for bronchial asthma, asthmatic bronchitis, obstructive pulmonary emphysema, and relief of wheezing symptoms [1] - The drug can also be used for wheezing caused by cardiogenic pulmonary edema [1] - Dihydroxypropyl Theophylline Injection was developed by Eisai Co., Ltd. and was launched in Japan in October 1952 [1] Group 2 - In August 2024, Xinyi Jinzhu submitted a supplementary application to the NMPA for the new specification and combined consistency evaluation of the generic drug, which was accepted [1] - As of the date of the announcement, the company has invested approximately RMB 3.05 million in research and development costs for this drug [1]

Core Viewpoint - Shanghai Pharmaceuticals (601607.SH) announced that its subsidiary, Shanghai Xinyi Jinzhu Pharmaceutical Co., Ltd. (referred to as "Xinyi Jinzhu"), has received a Supplementary Application Approval Notice from the National Medical Products Administration (NMPA) for its Dihydroxypropyl Theophylline Injection, which has passed the consistency evaluation of generic drug quality and efficacy [1] Group 1 - The Dihydroxypropyl Theophylline Injection is indicated for bronchial asthma, asthmatic bronchitis, obstructive pulmonary emphysema, and relief of wheezing symptoms [1] - The drug can also be used for wheezing caused by cardiogenic pulmonary edema [1] - The drug was developed by Eisai Co., Ltd. and was launched in Japan in October 1952 [1] Group 2 - In August 2024, Xinyi Jinzhu submitted a supplementary application to the NMPA for the new specification and consistency evaluation of the generic drug, which has been accepted [1] - As of the date of the announcement, the company has invested approximately RMB 3.05 million in research and development costs for this drug [1]

呈交日期: 2025年9月2日 I. 法定/註冊股本變動 FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年8月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 上海醫藥集團股份有限公司 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02607 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 919,072,704 | RMB | | 1 RMB | | 919,072,704 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 919,072,704 | RMB | | 1 RMB | | 919,072,704 | | 2. 股份分類 | 普通股 | 股份類別 | A ...

证券代码：601607 证券简称：上海医药 编号：临2025-080 上海医药集团股份有限公司 关于盐酸维拉帕米注射液通过仿制药一致性评价的公告 注册分类：化学药品 申请人：上海禾丰制药有限公司 药品批准文号：国药准字H31021343 审批结论：本品通过仿制药质量和疗效一致性评价。 二、该药品相关的信息 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担个别及连带责任。 近日，上海医药集团股份有限公司（以下简称"公司"）下属上海禾丰制药有限公司（以下简称"上药禾 丰"）的盐酸维拉帕米注射液（以下简称"该药品"）收到国家药品监督管理局（以下简称"国家药监 局"）颁发的《药品补充申请批准通知书》（通知书编号：2025B03892），该药品通过仿制药质量和疗 效一致性评价。 一、该药品基本情况 药品名称：盐酸维拉帕米注射液 剂型：注射剂 规格：2ml:5mg 根据国家相关政策，通过一致性评价的品种在医保支付及医疗机构采购等领域将获得更大的支持力度。 因此上药禾丰的盐酸维拉帕米注射液通过仿制药一致性评价，有利于扩大该药品的市场份额，提升市场 竞争 ...

Group 1 - Shanghai Pharmaceutical Group Co., Ltd. announced that its subsidiary, Shanghai Hefeng Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the consistency evaluation of the quality and efficacy of Verapamil Hydrochloride Injection [1][2] - The drug is primarily used for the rapid conversion of paroxysmal supraventricular tachycardia and for temporary control of ventricular rate in atrial flutter or atrial fibrillation [1][2] - The company has invested approximately RMB 3.29 million in research and development for this drug's consistency evaluation [1] Group 2 - As of the announcement date, there is one other company, Sichuan Meida Kangjiale Pharmaceutical Co., Ltd., that has also been deemed to have passed the consistency evaluation for this drug in China [2] - The IQVIA database indicates that the total procurement amount for Verapamil Hydrochloride Injection in hospitals in mainland China for 2024 is RMB 148.51 million [2] - The approval for consistency evaluation is expected to enhance the market share and competitiveness of Shanghai Hefeng's Verapamil Hydrochloride Injection, while also providing valuable experience for future product evaluations [2]